Pathologic staging of prostate carcinoma

What are the issues?

David Grignon, Wael A. Sakr

Research output: Contribution to journalArticle

51 Citations (Scopus)

Abstract

BACKGROUND. Stage is a significant predictor or outcome for patients with caret noma of the prostate. The American Joint Committee on Cancer (AJCC) and the International Union Against Cancer (UICC) TNM staging system has gained general favor as the clinical staging system of choice for prostate carcinoma. With an increasing number of publications assessing prognostic markers for patients with carcinoma of the prostate, there is a need for the development of a uniform system of pathologic staging to support the clinical stage. METHODS. The literature related to pathologic prognostic markers for patients with carcinoma of the prostate, particularly with regard to staging, was reviewed. From this, issues important to the development of a parhologic correlate to the AJCC UICC TNM system were identified. RESULTS. A number of issues were identified related to the development of a pathologic staging system. For radical prostatectomy specimens some of the more important are whether or not subcategorization is needed in the pathologic classification of T2 tumors, definition and quantification of extraprostatic extension, and the reporting of positive surgical margins. CONCLUSIONS. There is a need for the development of a pathologic equivalent to the AJCC/UICC TNM clinical staging system for prostate carcinoma. Consensus needs to be reached on several important issues prior to the adoption and testing of such a system.

Original languageEnglish (US)
Pages (from-to)337-340
Number of pages4
JournalCancer
Volume78
Issue number2
DOIs
StatePublished - Jul 15 1996
Externally publishedYes

Fingerprint

Prostate
Neoplasm Staging
Carcinoma
Neoplasms
Noma
Prostatectomy
Publications

Keywords

  • cancer
  • prostate
  • stage
  • TNM

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Pathologic staging of prostate carcinoma : What are the issues? / Grignon, David; Sakr, Wael A.

In: Cancer, Vol. 78, No. 2, 15.07.1996, p. 337-340.

Research output: Contribution to journalArticle

Grignon, David ; Sakr, Wael A. / Pathologic staging of prostate carcinoma : What are the issues?. In: Cancer. 1996 ; Vol. 78, No. 2. pp. 337-340.
@article{a85779d47e434324a3217fc81c5c3cc4,
title = "Pathologic staging of prostate carcinoma: What are the issues?",
abstract = "BACKGROUND. Stage is a significant predictor or outcome for patients with caret noma of the prostate. The American Joint Committee on Cancer (AJCC) and the International Union Against Cancer (UICC) TNM staging system has gained general favor as the clinical staging system of choice for prostate carcinoma. With an increasing number of publications assessing prognostic markers for patients with carcinoma of the prostate, there is a need for the development of a uniform system of pathologic staging to support the clinical stage. METHODS. The literature related to pathologic prognostic markers for patients with carcinoma of the prostate, particularly with regard to staging, was reviewed. From this, issues important to the development of a parhologic correlate to the AJCC UICC TNM system were identified. RESULTS. A number of issues were identified related to the development of a pathologic staging system. For radical prostatectomy specimens some of the more important are whether or not subcategorization is needed in the pathologic classification of T2 tumors, definition and quantification of extraprostatic extension, and the reporting of positive surgical margins. CONCLUSIONS. There is a need for the development of a pathologic equivalent to the AJCC/UICC TNM clinical staging system for prostate carcinoma. Consensus needs to be reached on several important issues prior to the adoption and testing of such a system.",
keywords = "cancer, prostate, stage, TNM",
author = "David Grignon and Sakr, {Wael A.}",
year = "1996",
month = "7",
day = "15",
doi = "10.1002/(SICI)1097-0142(19960715)78:2<337::AID-CNCR23>3.0.CO;2-W",
language = "English (US)",
volume = "78",
pages = "337--340",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "2",

}

TY - JOUR

T1 - Pathologic staging of prostate carcinoma

T2 - What are the issues?

AU - Grignon, David

AU - Sakr, Wael A.

PY - 1996/7/15

Y1 - 1996/7/15

N2 - BACKGROUND. Stage is a significant predictor or outcome for patients with caret noma of the prostate. The American Joint Committee on Cancer (AJCC) and the International Union Against Cancer (UICC) TNM staging system has gained general favor as the clinical staging system of choice for prostate carcinoma. With an increasing number of publications assessing prognostic markers for patients with carcinoma of the prostate, there is a need for the development of a uniform system of pathologic staging to support the clinical stage. METHODS. The literature related to pathologic prognostic markers for patients with carcinoma of the prostate, particularly with regard to staging, was reviewed. From this, issues important to the development of a parhologic correlate to the AJCC UICC TNM system were identified. RESULTS. A number of issues were identified related to the development of a pathologic staging system. For radical prostatectomy specimens some of the more important are whether or not subcategorization is needed in the pathologic classification of T2 tumors, definition and quantification of extraprostatic extension, and the reporting of positive surgical margins. CONCLUSIONS. There is a need for the development of a pathologic equivalent to the AJCC/UICC TNM clinical staging system for prostate carcinoma. Consensus needs to be reached on several important issues prior to the adoption and testing of such a system.

AB - BACKGROUND. Stage is a significant predictor or outcome for patients with caret noma of the prostate. The American Joint Committee on Cancer (AJCC) and the International Union Against Cancer (UICC) TNM staging system has gained general favor as the clinical staging system of choice for prostate carcinoma. With an increasing number of publications assessing prognostic markers for patients with carcinoma of the prostate, there is a need for the development of a uniform system of pathologic staging to support the clinical stage. METHODS. The literature related to pathologic prognostic markers for patients with carcinoma of the prostate, particularly with regard to staging, was reviewed. From this, issues important to the development of a parhologic correlate to the AJCC UICC TNM system were identified. RESULTS. A number of issues were identified related to the development of a pathologic staging system. For radical prostatectomy specimens some of the more important are whether or not subcategorization is needed in the pathologic classification of T2 tumors, definition and quantification of extraprostatic extension, and the reporting of positive surgical margins. CONCLUSIONS. There is a need for the development of a pathologic equivalent to the AJCC/UICC TNM clinical staging system for prostate carcinoma. Consensus needs to be reached on several important issues prior to the adoption and testing of such a system.

KW - cancer

KW - prostate

KW - stage

KW - TNM

UR - http://www.scopus.com/inward/record.url?scp=0029682313&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029682313&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1097-0142(19960715)78:2<337::AID-CNCR23>3.0.CO;2-W

DO - 10.1002/(SICI)1097-0142(19960715)78:2<337::AID-CNCR23>3.0.CO;2-W

M3 - Article

VL - 78

SP - 337

EP - 340

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 2

ER -